Anti-GD2 monoclonal antibody (specialist)
Dinutuximab beta
Brand names: Qarziba
Adult dose
Dose: 100mg/m²/cycle as continuous IV infusion over 10 days q5w (or per protocol); paediatric dosing
Route: IV
Frequency: Per cycle, q5 weeks
Clinical pearls
- NICE TA538: high-risk neuroblastoma in children
- Specialist paediatric oncology — Royal Marsden, GOSH, Birmingham, Manchester, Bristol
- Continuous opioid (often morphine) infusion mandatory throughout
Contraindications
- GVHD
- Active hypersensitivity
- Severe bone marrow failure
Side effects
- Severe pain (GD2-related — opioid analgesia infusion required)
- Hypersensitivity / anaphylaxis
- Capillary leak syndrome
- Fever
- Hypotension
- Diarrhoea
- Ocular toxicity (mydriasis)
- Peripheral neuropathy
Interactions
- Live vaccines
- Other immunosuppressives
Monitoring
- Pain
- BP
- FBC
- Capillary leak signs
- Eye review
- Infusion reactions
Reference: BNF; NICE TA538; CCLG protocol; SmPC; https://bnf.nice.org.uk/drugs/dinutuximab-beta-specialist-drug/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- MAGGIC Heart Failure Risk Score · Heart Failure
- Long QT Syndrome (Schwartz Score) · Channelopathy / Sudden Cardiac Death
- C-Peptide to Glucose Ratio · Diabetes Classification
- Revised Original International Autoimmune Hepatitis Score (IAIHG) · Autoimmune Liver Disease
- Ho Index for Predicting Response to Medical Therapy in IBD · Inflammatory Bowel Disease
- International Staging System (ISS) for Multiple Myeloma · Multiple Myeloma
Pathways